Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations

Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations

Abstract Background The cost of new anticancer drugs is rising. We aimed to assess the clinical benefit and price of anti‐cancer drugs approved by the US Food and Drug Administration (FDA) for advanced gastrointestinal cancers. Methods Drugs approved between 2006 and 2017 for advanced GI malignancie...

Full description

Bibliographic Details
Main Authors: Di Maria Jiang, Kelvin K. W. Chan, Raymond W. Jang, Christopher Booth, Geoffrey Liu, Eitan Amir, Robert Mason, Louis Everest, Elena Elimova
Format: Article
Language:English
Published: Wiley 2019-04-01
Series:Cancer Medicine
Subjects:
antineoplastic agents
clinical benefit
drug costs
gastrointestinal neoplasms
United States Food and Drug Administration
Online Access:https://doi.org/10.1002/cam4.2058

Internet

https://doi.org/10.1002/cam4.2058

Similar Items